Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias
Article 2025 en
Authors
VJ
Vikash Jaiswal
SA
Song Peng Ang
DK
Danisha Kumar
Abstract
1 min read
SGLT2i therapy was associated with an overall lower risk of atrial arrythmia and SCD in patients with type 2 diabetes mellitus and/or HF or chronic kidney disease. However, SGLT2i therapy was not associated with a lower risk of ventricular arrhythmia.
Discussion(0)
No comments yet. Be the first to comment.